EPISODE · Mar 11, 2026 · 13 MIN
Barclays Miami: Xencor CEO Bassil Dahiyat discusses the company's internal pipeline and how bi-specifics and other modalities are engineered to be increasingly sophisticated and more precise
from BiotechTV - News · host BiotechTV
He highlights pipeline programs targeting ENPP3, CLDN6, CLDN18.2, TL1A (including TL1A x IL23p19), CD20 x CD3, and CD19xCD3.
Embed this episode
Ready to play
Barclays Miami: Xencor CEO Bassil Dahiyat discusses the company's internal pipeline and how bi-specifics and other modalities are engineered to be increasingly sophisticated and more precise
0:00
13:10
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 13 minutes long.
When was this BiotechTV - News episode published?
This episode was published on March 11, 2026.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!